Perfluoroalkyl Substances and Abdominal Aortic Calcification.
Journal
Journal of occupational and environmental medicine
ISSN: 1536-5948
Titre abrégé: J Occup Environ Med
Pays: United States
ID NLM: 9504688
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
pubmed:
11
1
2022
medline:
28
4
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
To evaluate if serum perfluoroalkylated substances (PFAS) were associated with abdominal aortic calcification (AAC). We used weighted logistic regression to investigate the gender-specific association between PFAS serum levels and AAC more than or equal to 6 from dual-energy X-ray absorptiometry (DXA) scans of the thoraco-lumbar spine from National Health and Nutrition Examination Survey 2013-2014 survey participants aged more than or equal to 40 years. After adjusting for confounding, none of log-transformed perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS), perfluorohexane sulfonic acid (PFHxS), or perfluorononanoic acid (PFNA) were significantly associated with AAC for either men or women (adjusted odds ratios [ORs] ranged from 0.80 to 1.33, P > 0.05 each). For PFOA and PFOS, the association was positive only in women (although the difference was not statistically significant in either case). These findings do not provide general support for a relationship of PFAS exposure to AAC, although the results show a need for gender-specific consideration in a larger dataset.
Identifiants
pubmed: 35001069
doi: 10.1097/JOM.0000000000002479
pii: 00043764-202204000-00003
doi:
Substances chimiques
Alkanesulfonic Acids
0
Caprylates
0
Environmental Pollutants
0
Fluorocarbons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-294Informations de copyright
Copyright © 2022 American College of Occupational and Environmental Medicine.
Déclaration de conflit d'intérêts
Conflicts of Interest: A.D. has been a paid consultant to three communities seeking class action relief for PFAS contamination (payers include Faraci Lange, Motley Rice, Langrock Sperry, and Cohen Milstein), and a volunteer consultant to community leaders concerned about PFAS contamination in multiple settings. In addition, A.D. has provided unpaid lectures or service concerning PFAS to the Michigan State Medical State Medical Society, the US Government Accounting Office, the Australian Land and Groundwater Association, a committee of the National Academies of Sciences, Engineering and Medicine, the Agency for Toxics Substances and Disease Control, and the Centers for Disease Control and Prevention. Koskela, Ducatman, Schousboe, Nahhas, and Khalil have no relationships/conditions/circumstances that present potential conflict of interest.
Références
EFSA Panel on Contaminants in the Food Chain (EFSA CONTAM Panel), Schrenk D, Bignami M, et al. Risk to human health related to the presence of perfluoroalkyl substances in food. Efsa J. 2020; 18:e06223.
Buck RC, Franklin J, Berger U, et al. Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins. Integr Environ Assess Manag 2011; 7:513–541.
Chang ET, Adami H, Boffetta P, Wedner HJ, Mandel JS. A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and immunological health conditions in humans. Crit Rev Toxicol 2016; 46:279–331.
Lind PM, Lind L. Are persistent organic pollutants linked to lipid abnormalities, atherosclerosis and cardiovascular disease? A review. J Lipid Atheroscler 2020; 9:334–348.
Jensen RC, Andersen MS, Larsen PV, et al. Prenatal exposures to perfluoroalkyl acids and associations with markers of adiposity and plasma lipids in infancy: an odense child cohort study. Environ Health Perspect 2020; 128:77001.
Shankar A, Xiao J, Ducatman A. Perfluorooctanoic acid and cardiovascular disease in US adults. Arch Intern Med 2012; 172:1397–1403.
Frisbee SJ, Shankar A, Knox SS, et al. Perfluorooctanoic acid, perfluor-ooctanesulfonate, and serum lipids in children and adolescents: results from the C8 health project. Arch Pediatr Adolesc Med 2010; 164:860–869.
Fu Y, Wang T, Fu Q, Wang P, Lu Y. Associations between serum concentrations of perfluoroalkyl acids and serum lipid levels in a chinese population. Ecotoxicol Environ Saf 2014; 106:246–252.
Eriksen KT, Raaschou-Nielsen O, McLaughlin JK, et al. Association between plasma PFOA and PFOS levels and total cholesterol in a middleaged danish population. PLoS ONE 2013; 8:e56969.
Seo S, Son M, Choi S, Lee D, Chang Y. Influence of exposure to perfluoroalkyl substances (PFASs) on the korean general population: 10-year trend and health effects. Environ Int 2018; 113:149–161.
Blomberg AJ, Shih Y, Messerlian C, Jørgensen LH, Weihe P, Grandjean P. Early-life associations between per- and polyfluoroalkyl substances and serum lipids in a longitudinal birth cohort. Environ Res 2021; 200:111400.
Lin PD, Cardenas A, Hauser R, et al. Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults-longitudinal analysis of the diabetes prevention program outcomes study. Environ Int 2019; 129:343–353.
Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol 2009; 170:1268–1278.
Winquist A, Steenland K. Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. Environ Health Perspect 2014; 122:1299–1305.
Blake BE, Fenton SE. Early life exposure to per- and polyfluoroalkyl substances (PFAS) and latent health outcomes: a review including the placenta as a target tissue and possible driver of peri- and postnatal effects. Toxicology 2020; 443:152565.
Koskela A, Koponen J, Lehenkari P, Viluksela M, Korkalainen M, Tuukkanen J. Perfluoroalkyl substances in human bone: concentrations in bones and effects on bone cell differentiation. Sci Rep 2017; 7:6841.
Khalil N, Ebert JR, Honda M, et al. Perfluoroalkyl substances, bone density, and cardio-metabolic risk factors in obese 8-12year old children: a pilot study. Environ Res 2018; 160:314–321.
Di Nisio A, Rocca MS, De Toni L, et al. Endocrine disruption of vitamin D activity by perfluoro-octanoic acid (PFOA). Sci Rep 2020; 10:16789.
Perez F, Nadal M, Navarro-Ortega A, et al. Accumulation of perfluoroalkyl substances in human tissues. Environ Int 2013; 59:354–362.
Lind PM, Salihovic S, van Bavel B, Lind L. Circulating levels of perfluoroalkyl substances (PFASs) and carotid artery atherosclerosis. Environ Res 2017; 152:157–164.
Lin CY, Lin LY, Wen TW, et al. Association between levels of serum perfluorooctane sulfate and carotid artery intima-media thickness in adolescents and young adults. Int J Cardiol 2013; 168:3309–3316.
Criqui MH, Denenberg JO, McClelland RL, et al. Abdominal aortic calcium, coronary artery calcium, and cardiovascular morbidity and mortality in the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol 2014; 34:1574–1579.
Wilson PW, Kauppila LI, O’Donnell CJ, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001; 103:1529–1534.
CDC. National Center for Health Statistics. National Health and Nutrition Examination Survey: Questionnaires, Datasets, and Related Documentation; 2020. Available at: https://Wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2013 . Accessed December 17, 2020.
Schousboe JT, Lewis JR, Kiel DP. Abdominal aortic calcification on dual-energy X-ray absorptiometry: methods of assessment and clinical significance. Bone 2017; 104:91–100.
Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PWF. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 1997; 132:245–250.
Schousboe JT, Wilson KE, Kiel DP. Detection of abdominal aortic calcification with lateral spine imaging using DXA. J Clin Densitom 2006; 9:302–308.
Bazzocchi A, Ciccarese F, Diano D, et al. Dual-energy X-ray absorptiometry in the evaluation of abdominal aortic calcifications. J Clin Densitom 2012; 15:198–204.
Leow K, Szulc P, Schousboe JT, et al. Prognostic value of abdominal aortic calcification: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2021; 10:e017205.
Kuklenyik Z, Needham LL, Calafat AM. Measurement of 18 perfluorinated organic acids and amides in human serum using on-line solid-phase extraction. Anal Chem 2005; 77:6085–6091.
Benskin JP, De Silva AO, Martin JW. Isomer profiling of perfluorinated substances as a tool for source tracking: a review of early findings and future applications. Rev Environ Contam Toxicol 2010; 208:111–160.
Khalil N, Chen A, Lee M, et al. Association of perfluoroalkyl substances, bone mineral density, and osteoporosis in the U.S. population in NHANES 2009–2010. Environ Health Perspect 2016; 124:81–87.
Huang M, Jiao J, Zhuang P, Chen X, Wang J, Zhang Y. Serum polyfluoroalkyl chemicals are associated with risk of cardiovascular diseases in national US population. Environ Int 2018; 119:37–46.
Lind PM, Salihovic S, Stubleski J, Karrman A, Lind L. Changes in plasma levels of perfluoroalkyl substances (PFASs) are related to increase in carotid intima-media thickness over 10 years - a longitudinal study. Environ Health 2018; 17:59.
Mattsson K, Rignell-Hydbom A, Holmberg S, et al. Levels of perfluoroalkyl substances and risk of coronary heart disease: findings from a population-based longitudinal study. Environ Res 2015; 142:148–154.
Hutcheson R, Innes K, Conway B. Perfluoroalkyl substances and likelihood of stroke in persons with and without diabetes. Diab Vasc Dis Res 2020; 17:1479164119892223.
Allison MA, Budoff MJ, Nasir K, et al. Ethnic-specific risks for atherosclerotic calcification of the thoracic and abdominal aorta (from the multi-ethnic study of atherosclerosis). Am J Cardiol 2009; 104:812–817.
Kim D, Diez Roux AV, Kiefe CI, Kawachi I, Liu K. Do neighborhood socioeconomic deprivation and low social cohesion predict coronary calcification?: the CARDIA study. Am J Epidemiol 2010; 172:288–298.
Hukkanen J, Jacob P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57:79–115.
CDC (Centers for Disease Control and Prevention). Fourth Report on Human Exposure to Environmental Chemicals, 2009. Atlanta, GA: U.S. Department Of Health And Human Services, Centers For Disease Control And Prevention; 2019. Available at: https://Www.cdc.gov/exposurereport/ . Accessed December 23, 2020.
NCHS (National Center for Health Statistics) NHANES tutorials; 2020. Available at: Https://Wwwn.cdc.gov/nchs/nhanes/tutorials/default.aspx . Accessed December 23, 2020.
Fenton SE, Ducatman A, Boobis A, et al. Per- and polyfluoroalkyl substance toxicity and human health review: current state of knowledge and strategies for informing future research. Environ Toxicol Chem 2021; 40:606–630.
Barascuk N, Ganz M, Nielsen M, et al. Abdominal aortic calcification quantified by the morphological atherosclerotic calcification distribution (MACD) index is associated with features of the metabolic syndrome. BMC Cardiovasc Disord 2011; 11:75.
Ma S, Xu C, Ma J, et al. Association between perfluoroalkyl substance concentrations and blood pressure in adolescents. Environ Pollut 2019; 254:112971.
Pitter G, Zare Jeddi M, Barbieri G, et al. Perfluoroalkyl substances are associated with elevated blood pressure and hypertension in highly exposed young adults. Environ Health 2020; 19:102.
Lin CY, Chen PC, Lo SC, Torng PL, Sung FC, Su TC. The association of carotid intima-media thickness with serum level of perfluorinated chemicals and endothelium-platelet microparticles in adolescents and young adults. Environ Int 2016; 94:292–299.
Bolland MJ, Wang TKM, van Pelt NC, et al. Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. J Bone Miner Res 2010; 25:505–512.
Omoike OE, Pack RP, Mamudu HM, et al. Association between per and polyfluoroalkyl substances and markers of inflammation and oxidative stress. Environ Res 2021; 196:110361.
Qian Y, Ducatman A, Ward R, et al. Perfluorooctane sulfonate (PFOS) induces reactive oxygen species (ROS) production in human microvascular endothelial cells: role in endothelial permeability. J Toxicol Environ Health A 2010; 73:819–836.
Deng P, Wang C, Wahlang B, Sexton T, Morris AJ, Hennig B. Co-exposure to PCB126 and PFOS increases biomarkers associated with cardiovascular disease risk and liver injury in mice. Toxicol Appl Pharmacol 2020; 409:115301.
De Toni L, Radu CM, Sabovic I, et al. Increased cardiovascular risk associated with chemical sensitivity to perfluoro-octanoic acid: role of impaired platelet aggregation. Int J Mol Sci 2020; 21:0108.
Li Y, Fletcher T, Mucs D, et al. Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. Occup Environ Med 2018; 75:46–51.
Xu Y, Fletcher T, Pineda D, et al. Serum half-lives for short- and long-chain perfluoroalkyl acids after ceasing exposure from drinking water contaminated by firefighting foam. Environ Health Perspect 2020; 128:77004.